We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Level up your trading with our powerful tools and real-time insights all in one place.
The current ACRX market cap is 14.58M. The company's latest EPS is USD -1.0852 and P/E is -0.79.
| Quarter End | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 253k | 117k | 281k | 0 | 0 |
| Operating Income | -3.97M | -3.31M | -4.28M | -4.24M | -4.27M |
| Net Income | -4.37M | -1.36M | -4.52M | -3.95M | -3.83M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 2.29M | 5.42M | 2.82M | 1.77M | 651k |
| Operating Income | -54.21M | -40.96M | -35.97M | -36.63M | -16.89M |
| Net Income | -53.24M | -40.38M | -35.1M | 42.33M | -18.4M |
| Quarter End | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 17.73M | 23.26M | 20.4M | 28.77M | 24.86M |
| Total Liabilities | 7.31M | 4.95M | 6.29M | 12.44M | 12.13M |
| Total Equity | 10.42M | 18.31M | 14.11M | 16.33M | 12.73M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 91.36M | 66.3M | 77.89M | 47.49M | 20.4M |
| Total Liabilities | 132.77M | 122.05M | 113.79M | 25.67M | 6.29M |
| Total Equity | -41.42M | -55.75M | -35.89M | 21.81M | 14.11M |
| Quarter End | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -10.58M | -13.54M | -17.49M | -2.88M | -7.49M |
| Investing | 3.12M | 3.12M | -528k | -2.73M | 3.18M |
| Financing | -5.41M | 3.53M | 3.47M | 12.01M | 12.01M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -51.18M | -38.51M | -30M | -28.33M | -17.49M |
| Investing | -36.56M | 34.14M | -26.12M | 36.45M | -528k |
| Financing | 14.45M | 16.96M | 41.51M | -507k | 3.47M |
| Market Cap | 14.58M |
| Price to Earnings Ratio | -0.79 |
| Price to Sales Ratio | 22.4 |
| Price to Cash Ratio | 2.55 |
| Price to Book Ratio | 1.03 |
| Dividend Yield | - |
| Shares Outstanding | 16.95M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | - |
| 52 Week High | - |
| 52 Week Low | - |
| Spread (Intraday) | 0.03 (3.26%) |
| Company Name | AcelRX Pharmaceuticals Inc |
| Address |
251 little falls drive wilmington, delaware 19808 |
| Website | https://talphera.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
